<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842073</url>
  </required_header>
  <id_info>
    <org_study_id>16-1370</org_study_id>
    <secondary_id>TTSA018P1</secondary_id>
    <nct_id>NCT02842073</nct_id>
  </id_info>
  <brief_title>An Open Label Trial of Bupropion and Naltrexone for Binge Drinking</brief_title>
  <official_title>Assessing Changes in the Brain Melanocortin System and Sensory Processing in Response to Alcohol to Advance Our Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Carolina Translational and Clinical Sciences Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase IIa pilot study of the tolerability and effects on binge drinking
      of bupropion and naltrexone for binge drinkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label Phase IIa pilot study of the tolerability and effects on binge drinking
      of bupropion and naltrexone for binge drinkers.

      Participants: Investigators will recruit 12 men or women ages 21-34 years who exhibit a
      minimum of 5/3 (men/women) or more binge drinking episodes per month over the past three
      months. A binge drinking episode is defined as the consumption of 5/4 (men/women) standard
      drinks (~12 gms ethanol) in about a two hour period. Subjects may meet DSM-V criteria for
      mild or moderate alcohol use disorder. Subjects with overt physical dependence on alcohol,
      significant medical problems including seizures or bulimia, other substance use disorder
      except for occasional marijuana (based on toxicology screen) or significant psychiatric
      illness will be excluded.

      Procedures (methods): As a first step in human trials investigators will give open label
      bupropion + naltrexone to active binge drinking subjects. The primary goal here is to assess
      tolerability and acceptability though changes in binge drinking and subjective sense of
      &quot;effect&quot; will be gathered as well. Investigators will also test cortical adaptation to binge
      drinking by completing tactile sensory testing and comparing the results to controls and
      individuals with overt physical dependence on alcohol. Investigators will recruit subjects
      using the e-mail listserve for UNC students, faculty and staff.

      Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk)
      and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will
      be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will
      be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84. Subjects will be
      seen at screening and then at Weeks 0, 1, 3, 5, 8 and 12. Subjects will be breathalyzed and
      receive Medical Management counseling to encourage compliance and progress towards drinking
      goals. Investigators will use the Time Line Follow-Back approach to assess alcohol
      consumption history modified to include time taken to consume alcohol and define a binge.
      They will also measure craving for alcohol and will assess tolerability by probing for
      adverse effects. Key outcomes of interest include tolerability and acceptability, drinking
      behavior including frequency and intensity of binge drinking, and craving for alcohol.
      Because this is an open-label trial without a placebo comparison group no formal statistics
      will be completed and efficacy will not be assessed. Instead, this pilot study will inform
      investigators about the recruitment of binge drinkers, the tolerability and acceptability of
      bupropion/naltrexone in this population and potential efficacy signals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Actual">December 13, 2017</completion_date>
  <primary_completion_date type="Actual">December 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Associated Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tolerability assessed by specifically probing for intervention-associated adverse effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Subsequent to Defined Intolerance</measure>
    <time_frame>Throughout study, a total of approximately 12 weeks</time_frame>
    <description>Retention was evaluated indirectly by accounting for those participants who discontinued either naltrexone or bupropion or study participation itself due to intolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Binge Drinking Days During Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of binge drinking days during treatment with bupropion + naltrexone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final Penn Alcohol Craving Scale (PACS) Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Craving for alcohol will be assessed using the Penn Alcohol Craving Scale (PACS) The PACS is a five-item self-administered instrument for assessing craving. Frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking. The final item asks the responder to provide an average rating of his/her craving over the course of the past week. The questions on the PACS use descriptors coupled with numerical ratings ranging from 0 to 6 with the highest possible total score of 30. Higher scores reflect a higher level of craving. This outcome measure is the final PACS total score obtained in the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Drinks/Binge Drinking Day During Treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Binge Drinking</condition>
  <arm_group>
    <arm_group_label>Naltrexone and Buproprion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.</description>
    <arm_group_label>Naltrexone and Buproprion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.</description>
    <arm_group_label>Naltrexone and Buproprion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 21 and 34 years.

          2. A minimum of 5/3 (men/women) or more binge drinking episodes per month over the past
             three months. A binge drinking episode is defined as the consumption of 5/4
             (men/women) standard drinks (~12 gms ethanol) in about a two hour period. Subjects may
             meet DSM-V criteria for mild or moderate alcohol use disorder.

          3. Ability to understand and sign written informed consent.

          4. Must have a 0.0 gms/dl breathalyzer reading on the day of screening and 0.0 gms/dl on
             the day of randomization.

          5. Must have a stable residence and be able to identify an individual who could contact
             participant if needed.

          6. Have a goal of sobriety or significantly reducing alcohol intake.

        Exclusion Criteria

          1. Presence of physical dependence on alcohol as assessed by clear tolerance to alcohol
             or alcohol withdrawal symptoms based on SCID interview or a Severe Alcohol Use
             Disorder (&gt;5 SCID DSM-V symptoms).

          2. Bupropion is contraindicated in individuals with a history of bulimia or a seizure
             disorder and naltrexone is contraindicated in acute liver disease and in patients
             using or misusing opioids.

          3. Clinically significant medical disease that might interfere with the evaluation of the
             study medication or present a safety concern (e.g., renal insufficiency, cirrhosis,
             unstable hypertension, diabetes mellitus, seizure disorder). Clinically significant
             psychiatric illness including any psychotic disorder, bipolar disorder,
             anorexia/bulimia, severe depression, or suicidal ideation.

          4. Other substance abuse or dependence disorder other than nicotine or cannabis abuse.

          5. Concurrent use of anticonvulsants. Concurrent use of any psychotropic medication
             including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants,
             or hypnotics with the exception of stable doses of antidepressants for one month.
             Bupropion is commonly added to antidepressants for augmentation so the use of another
             antidepressant does not represent a safety concern. Prior history of adverse reaction
             to bupropion or naltrexone.

          6. AST or ALT &gt; 3.5 times ULN or bilirubin &gt; 1.5 X ULN.

          7. Positive urine toxicology screen with the exception of cannabis. Individuals with
             positive cannabis screens will be excluded only if they have a history of cannabis
             dependence.

          8. Pregnant women and women of childbearing potential who do not practice a medically
             acceptable form of birth control (oral or depot contraceptive, or barrier methods such
             as diaphragm or condom with spermicidal).

          9. Women who are breastfeeding.

         10. Individuals requiring inpatient treatment or more intense outpatient treatment for
             their alcohol problems.

         11. Participation in any clinical trial within the past 60 days that would have safety
             concerns for the trial.

         12. Court-mandated participation in alcohol treatment or pending incarceration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Garbutt</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>December 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2018</results_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Binge Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02842073/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone and Buproprion</title>
          <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone and Buproprion</title>
          <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Binge Drinking Days in 90 days prior to screening</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intensity of Binge Drinking prior to Study</title>
          <description>The mean number of drinks/binge drinking day in the 90 days prior to screening.</description>
          <units>drinks/binge drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Craving for Alcohol</title>
          <description>The PACS is a five-item self-administered instrument for assessing craving. Frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking. The final item asks the responder to provide an average rating of his/her craving over the course of the past week. The questions on the PACS use descriptors coupled with numerical ratings ranging from 0 to 6 with the highest possible total score of 30. Higher scores reflect a higher level of craving.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.25" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Associated Adverse Events</title>
        <description>Tolerability assessed by specifically probing for intervention-associated adverse effects.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Buproprion</title>
            <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Associated Adverse Events</title>
          <description>Tolerability assessed by specifically probing for intervention-associated adverse effects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Subsequent to Defined Intolerance</title>
        <description>Retention was evaluated indirectly by accounting for those participants who discontinued either naltrexone or bupropion or study participation itself due to intolerance.</description>
        <time_frame>Throughout study, a total of approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Buproprion</title>
            <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Subsequent to Defined Intolerance</title>
          <description>Retention was evaluated indirectly by accounting for those participants who discontinued either naltrexone or bupropion or study participation itself due to intolerance.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued: Naltrexone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued: Buproprion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued: Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Binge Drinking Days During Treatment</title>
        <description>The number of binge drinking days during treatment with bupropion + naltrexone</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Buproprion</title>
            <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Binge Drinking Days During Treatment</title>
          <description>The number of binge drinking days during treatment with bupropion + naltrexone</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Penn Alcohol Craving Scale (PACS) Score</title>
        <description>Craving for alcohol will be assessed using the Penn Alcohol Craving Scale (PACS) The PACS is a five-item self-administered instrument for assessing craving. Frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking. The final item asks the responder to provide an average rating of his/her craving over the course of the past week. The questions on the PACS use descriptors coupled with numerical ratings ranging from 0 to 6 with the highest possible total score of 30. Higher scores reflect a higher level of craving. This outcome measure is the final PACS total score obtained in the trial.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Buproprion</title>
            <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Penn Alcohol Craving Scale (PACS) Score</title>
          <description>Craving for alcohol will be assessed using the Penn Alcohol Craving Scale (PACS) The PACS is a five-item self-administered instrument for assessing craving. Frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking. The final item asks the responder to provide an average rating of his/her craving over the course of the past week. The questions on the PACS use descriptors coupled with numerical ratings ranging from 0 to 6 with the highest possible total score of 30. Higher scores reflect a higher level of craving. This outcome measure is the final PACS total score obtained in the trial.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Drinks/Binge Drinking Day During Treatment</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Buproprion</title>
            <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Drinks/Binge Drinking Day During Treatment</title>
          <units>drinks/binge drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the 12-week study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone and Buproprion</title>
          <description>Bupropion XL 150 mg/d on Days 1-4 increased to 300 mg/d for Days 5-84. Naltrexone 25 mg/d from Days 7-9 and increased to 50 mg/d for Days 10-84.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Low energy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Reduced Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C Garbutt, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>984-974-2201</phone>
      <email>jc_garbutt@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

